Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

CALCBullishCorporate Developmentsnews

High materiality9/10

CalciMedica raises up to $49M private placement to advance pulmonary hypertension program

Jun 24, 2026, 7:03 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Funding validates strategy and provides runway for key PH catalysts; dilution is a consideration but the private placement signals investor confidence and reduces near-term liquidity risk. Historically, biotech financings can trigger near-term volatility; the net effect depends on milestone timing and data readouts.

AI summary

What happened, with direct paths to the underlying reporting

CalciMedica disclosed a private placement for up to $49 million to fund its pulmonary hypertension strategy, including a capital-efficient Auxora Phase 1b study in PAH with data expected mid-2027 and IND timing for CM5480 in mid-2027. Proceeds also extend cash runway into the second half of 2027. The deal signals strong investor validation but introduces equity dilution and requires stockholder approval for warrants.

CALC to raise up to $49M via private placement with new and existing investors. Investors include board and management.
Upfront about $15M; Series A ($15M) and Series B ($19M) warrants could add $34M.
Funds to advance PAH program: Auxora Phase 1b in PAH mid-2027; CM5480 IND mid-2027.
Warrants require stockholder approval; insiders buy units priced at/above June 23, 2026 close.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

CalciMedica raises up to $49M private placement to advance pulmonary hypertension program

CalciMedica Pauses Kidney Study, Eyes New Trial In Pancreatitis